Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Clinical Trials

12 clinical trials for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer — RECRUITING · PHASE1
• Iparomlimab and Tuvonralimab in HNSCC — RECRUITING · PHASE2
• Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC — RECRUITING · PHASE2
• Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. — RECRUITING · PHASE2
• A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) — RECRUITING · PHASE2
• Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC — RECRUITING · PHASE2
• Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC — RECRUITING · PHASE2
• A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) — RECRUITING · PHASE2
• Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC — COMPLETED · PHASE2
• A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE2
• Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) — COMPLETED · PHASE2
• Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. — OTHER · PHASE2

Refine this search